Array Biopharma Inc
ARRY
ARRY was delisted on the 29th of July, 2019.
112 hedge funds and large institutions have $431M invested in Array Biopharma Inc in 2014 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 35 increasing their positions, 33 reducing their positions, and 28 closing their positions.
6% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 33
13% less funds holding
Funds holding: 129 → 112 (-17)
21% less capital invested
Capital invested by funds: $545M → $431M (-$113M)
28% less call options, than puts
Call options by funds: $1.81M | Put options by funds: $2.53M
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
57% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 28
Top Buyers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.62M |
| 2 |
PA
Pinnacle Associates
New York
|
+$4.45M |
| 3 |
State Street
Boston,
Massachusetts
|
+$4.23M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$2.32M |
| 5 |
QF
QVT Financial
New York
|
+$1.16M |
Top Sellers
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$3.31M |
| 2 |
SCM
Suffolk Capital Management
New York
|
-$2.13M |
| 3 |
AC
Apex Capital
Orinda,
California
|
-$1.97M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$1.08M |
| 5 |
ARC
Absolute Return Capital
Boston,
Massachusetts
|
-$817K |
ARRY Hedge Fund Activity: Q3 2014 in Review
112 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q3 2014, worth a combined $431M — down 21% from $545M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of ARRY and 12 opened new positions — a net loss of 16 holders — while 33 trimmed existing stakes and 35 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $5.62M. The largest seller was BVF Inc, cutting an estimated $3.31M.
- 112 institutional investors held Array Biopharma Inc (ARRY) as of Q3 2014, down from 129 in Q2 2014.
- Funds reported $431M of Array Biopharma Inc stock for Q3 2014, down 21% quarter-over-quarter.
- 12 funds opened new Array Biopharma Inc positions in Q3 2014 and 28 closed out, a net change of -16 holders.
- The largest Array Biopharma Inc buyer in Q3 2014 was Point72 Asset Management, an estimated $5.62M added.
- The largest Array Biopharma Inc seller in Q3 2014 was BVF Inc, an estimated $3.31M sold.
Based on aggregated 13F filings for Q3 2014.